产品和服务 / 产品类型 / 重组蛋白 / 其他蛋白

Recombinant Human LRRC15/LIB Protein (RP02705)

Human LRRC15 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

The purity of Human LRRC15 is greater than 95% as determined by SEC-HPLC.

Immobilized Human LRRC15, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Anti-LRRC15 Antibody, hFc Tag with the EC50 of 20.4ng/ml determined by ELISA.

All(3)|
货号: RP02705
促销价:   ¥3200
货    期:在线咨询货期
抗体定制
服务咨询
|
扫码下单
享受积分

详细信息

种属
Human
表达宿主
HEK293 cells
Calculated MW
60.7 kDa
Observed MW
70-80 kDa
标签
C-His&Avi
纯度
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC
内毒素
Less than 1EU per μg by the LAL method.
描述
Recombinant Human LRRC15/LIB Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal.;It contains Tyr22-Gly538.
储存
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月;
复溶之后,蛋白溶液在-20°C及以下可保存3个月,在2-8℃可保存1周。
复溶
Centrifuge the tube before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底,如果粉末浮起,开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL(请注意蛋白复溶浓度不能低于0.1 mg/mL),室温平衡5-10 min保证充分溶解,复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存,建议复溶时添加载体蛋白或者稳定剂(如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖),同时将复溶后的蛋白溶液按照需求进行分装,储存于-20°C至-80°C,随取随用,避免反复冻融。

蛋白复溶计算器

请在蛋白复溶计算器中输入蛋白总质量和所需终浓度,快速计算您需要添加溶液的体积吧!
=
÷

客户数据及评论 (0)

折叠内容

背景信息

The chimeric protein binds in vitro and in vivo to a specific element upstream of LRRC15, leading to dramatic transcriptional activation.? LRRC15 encodes a leucine-rich transmembrane protein, present at the leading edge of migrating cells, the expression of which in normal tissues is restricted to the invasive cytotrophoblast layer of the placenta; small interfering (siRNA)-mediated suppression of LRRC15 expression in breast cancer cells leads to abrogation of invasiveness in vitro.